open access

Vol 71, No 4 (2020)
Review paper
Published online: 2020-08-14
Submitted: 2020-03-24
Accepted: 2020-04-28
Get Citation

Associations between renalase concentration and the occurrence of selected diseases

Justyna Czubilińska-Łada, Aleksandra Gliwińska, Andrzej Badeński, Maria Szczepańska
DOI: 10.5603/EP.a2020.0044
·
Pubmed: 32852050
·
Endokrynologia Polska 2020;71(4):334-342.

open access

Vol 71, No 4 (2020)
Review Article
Published online: 2020-08-14
Submitted: 2020-03-24
Accepted: 2020-04-28

Abstract

Renalase is a recently identified flavoprotein oxidase, secreted mainly by the kidneys, which takes part in the degradation of catecholamines. The catecholamine inactivating effect results in the modulation of the sympathetic system tension and, consequently, in a decrease of blood pressure, myocardial contractility, heart rate, and vascular tone. Besides its enzymatic capacity, renalase shows cytoprotective properties by activating mitogen-activated protein kinase (MAPK) pathway. Several single nucleotide polymorphisms (SNPs) of the renalase gene have been identified, of which the most widely studied in relation to the development of selected diseases are rs2296545, rs10887800, and rs2576178. Numerous publications prove the contribution of renalase to the occurrence of cardiovascular diseases, kidney diseases, ischaemic stroke, diabetes type 1 and 2, as well as female infertility and schizophrenia. Further extended research into the various mechanisms of renalase activity may result in the use of this oxidase or its analogues as a therapeutic and/or diagnostic tool.

Abstract

Renalase is a recently identified flavoprotein oxidase, secreted mainly by the kidneys, which takes part in the degradation of catecholamines. The catecholamine inactivating effect results in the modulation of the sympathetic system tension and, consequently, in a decrease of blood pressure, myocardial contractility, heart rate, and vascular tone. Besides its enzymatic capacity, renalase shows cytoprotective properties by activating mitogen-activated protein kinase (MAPK) pathway. Several single nucleotide polymorphisms (SNPs) of the renalase gene have been identified, of which the most widely studied in relation to the development of selected diseases are rs2296545, rs10887800, and rs2576178. Numerous publications prove the contribution of renalase to the occurrence of cardiovascular diseases, kidney diseases, ischaemic stroke, diabetes type 1 and 2, as well as female infertility and schizophrenia. Further extended research into the various mechanisms of renalase activity may result in the use of this oxidase or its analogues as a therapeutic and/or diagnostic tool.

Get Citation

Keywords

renalase; catecholamines; cardiovascular diseases; kidney diseases

About this article
Title

Associations between renalase concentration and the occurrence of selected diseases

Journal

Endokrynologia Polska

Issue

Vol 71, No 4 (2020)

Article type

Review paper

Pages

334-342

Published online

2020-08-14

DOI

10.5603/EP.a2020.0044

Pubmed

32852050

Bibliographic record

Endokrynologia Polska 2020;71(4):334-342.

Keywords

renalase
catecholamines
cardiovascular diseases
kidney diseases

Authors

Justyna Czubilińska-Łada
Aleksandra Gliwińska
Andrzej Badeński
Maria Szczepańska

References (61)
  1. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005; 115(5): 1275–1280.
  2. Hennebry SC, Eikelis N, Socratous F, et al. Renalase, a novel soluble FAD-dependent protein, is synthesized in the brain and peripheral nerves. Mol Psychiatry. 2010; 15(3): 234–236.
  3. Zhou M, Liang T, Wang Y, et al. Expression and tissue localization of renalase, a novel soluble FAD-dependent protein, in reproductive/steroidogenic systems. Mol Biol Rep. 2013; 40(6): 3987–3994.
  4. Xu J, Desir GV. Renalase, a new renal hormone: its role in health and disease. Curr Opin Nephrol Hypertens. 2007; 16(4): 373–378.
  5. Wang F, Xing T, Li J, et al. Renalase's expression and distribution in renal tissue and cells. PLoS One. 2012; 7(10): e46442.
  6. Desir GV. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. Curr Opin Nephrol Hypertens. 2008; 17(2): 181–185.
  7. Li G, Xu J, Wang P, et al. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation. 2008; 117(10): 1277–1282.
  8. Beaupre BA, Carmichael BR, Hoag MR, et al. Renalase is an α-NAD(P)H oxidase/anomerase. J Am Chem Soc. 2013; 135(37): 13980–13987.
  9. Moran GR, Hoag MR. The enzyme: Renalase. Arch Biochem Biophys. 2017; 632: 66–76.
  10. Guo X, Wang L, Velazquez H, et al. Renalase: its role as a cytokine, and an update on its association with type 1 diabetes and ischemic stroke. Curr Opin Nephrol Hypertens. 2014; 23(5): 513–518.
  11. Wang L, Velazquez H, Chang J, et al. Identification of a receptor for extracellular renalase. PLoS One. 2015; 10(4): e0122932.
  12. Desir GV. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int. 2009; 76(4): 366–370.
  13. Lv YB, Wang Y, Ma WG, et al. Association of Renalase SNPs rs2296545 and rs2576178 with the Risk of Hypertension: A Meta-Analysis. PLoS One. 2016; 11(7): e0158880.
  14. Akbari H, Asadikaram G, Vakili S, et al. Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. J Cell Biochem. 2019; 120(6): 9159–9171.
  15. He B, Hao J, Sheng W, et al. Correlation between plasma renalase level and coronary artery disease. Pak J Med Sci. 2014; 30(5): 863–967.
  16. Hu N, Wang J, Hu P, et al. Investigation of Renalase gene rs2576178 polymorphism in patients with coronary artery disease. Biosci Rep. 2018; 38(5).
  17. Li X, Jiang W, Li L, et al. Renalase gene polymorphism in patients with hypertension and concomitant coronary heart disease. Kidney Blood Press Res. 2014; 39(1): 9–16.
  18. Stec A, Ksiazek A, Buraczynska M. Rs10887800 renalase gene polymorphism is associated with an increased risk of coronary artery disease in hemodialyzed patients. Int Urol Nephrol. 2016; 48(6): 871–876.
  19. Dickson ME, Sigmund CD. Genetic basis of hypertension: revisiting angiotensinogen. Hypertension. 2006; 48(1): 14–20.
  20. Banaszak B, Świętochowska E, Banaszak P, et al. Endothelin-1 (ET-1), N-terminal fragment of pro-atrial natriuretic peptide (NTpro-ANP), and tumour necrosis factor alpha (TNF-α) in children with primary hypertension and hypertension of renal origin. Endokrynol Pol. 2019; 70(1): 37–42.
  21. Krysiak R, Sierant M, Marek B, et al. The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Endokrynol Pol. 2010; 61(3): 280–287.
  22. Maciorkowska D, Zbroch E, Malyszko J. Circulating renalase, catecholamines, and vascular adhesion protein 1 in hypertensive patients. J Am Soc Hypertens. 2015; 9(11): 855–864.
  23. Wybraniec MT, Mizia-Stec K, Trojnarska O, et al. Low plasma renalase concentration in hypertensive patients after surgical repair of coarctation of aorta. J Am Soc Hypertens. 2014; 8(7): 464–474.
  24. Schlaich M, Socratous F, Eikelis N, et al. Renalase plasma levels are associated with systolic blood pressure in patients with resistant hypertension. J Hypertens. 2010; 28: e437.
  25. Zhao Qi, Fan Z, He J, et al. Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J Mol Med (Berl). 2007; 85(8): 877–885.
  26. Elsetohy KA, Al-Ghussein MA, Sabry D, et al. Are renalase rs2576178 and rs10887800 polymorphisms associated with pregnancy induced hypertension? World J Pharm Sci. 2014; 3(8): 177–192.
  27. Bagci B, Karakus S, Bagci G, et al. Renalase gene polymorphism is associated with increased blood pressure in preeclampsia. Pregnancy Hypertens. 2016; 6(2): 115–120.
  28. Teimoori B, Moradi-Shahrebabak M, Rezaei M, et al. Renalase rs10887800 polymorphism is associated with severe pre-eclampsia in southeast Iranian women. J Cell Biochem. 2019; 120(3): 3277–3285.
  29. Jamil Z, Shahid S, Baig E, et al. Serum anti mullerian hormone and renalase levels in predicting the risk of preeclampsia. Taiwan J Obstet Gynecol. 2019; 58(2): 188–191.
  30. Niadany SEl, Gayed AEl, Gayed EEl. Renalase rs10887800 gene polymorphism and its serum level in preeclampsia. Meta Gene. 2020; 24: 2214.
  31. Yılmaz ZV, Akkaş E, Yıldırım T, et al. A novel marker in pregnant with preeclampsia: renalase. J Matern Fetal Neonatal Med. 2017; 30(7): 808–813.
  32. Zbroch E, Malyszko J, Malyszko JS, et al. Renalase, a novel enzyme involved in blood pressure regulation, is related to kidney function but not to blood pressure in hemodialysis patients. Kidney Blood Press Res. 2012; 35(6): 395–399.
  33. Zbroch E, Koc-Zorawska E, Malyszko J, et al. Circulating levels of renalase, norepinephrine, and dopamine in dialysis patients. Ren Fail. 2013; 35(5): 673–679.
  34. Gluba-Brzózka A, Michalska-Kasiczak M, Franczyk-Skóra B, et al. Markers of increased cardiovascular risk in patients with chronic kidney disease. Lipids Health Dis. 2014; 13: 135.
  35. Baek SHa, Cha RH, Kang SW, et al. Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease. Korean J Intern Med. 2019; 34(4): 858–866.
  36. Skrzypczyk P, Okarska-Napierała M, Stelmaszczyk-Emmel A, et al. Renalase in children with chronic kidney disease. Biomarkers. 2019; 24(7): 638–644.
  37. Wiśniewska M, Serwin N, Dziedziejko V, et al. Chronic kidney disease is associated with increased levels of renalase in serum and decreased in erythrocytes. Pol Arch Intern Med. 2019; 129(11): 790–797.
  38. Pawlik A, Serdynska M, Dabrowska-Zamojcin E, et al. Renalase gene polymorphism in patients after renal allograft transplantation. Kidney Blood Press Res. 2014; 39(1): 58–64.
  39. Zbroch E, Małyszko J, Małyszko J, et al. Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients. Pol Arch Med Wewn . 2012; 122(1–2): 40–44.
  40. Buraczynska M, Zukowski P, Buraczynska K, et al. Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke. Neuromolecular Med. 2011; 13(4): 321–327.
  41. Li X, Wang Z, Liu Y, et al. Association of imaging classification of intracranial cerebral atherosclerotic vascular stenosis in ischemic stroke and renalase gene polymorphisms. J Mol Neurosci. 2014; 52(4): 461–466.
  42. Zhang R, Li X, Liu N, et al. An association study on renalase polymorphisms and ischemic stroke in a Chinese population. Neuromolecular Med. 2013; 15(2): 396–404.
  43. Malyszko J, Koc-Zorawska E, Malyszko JS, et al. Renalase, stroke, and hypertension in hemodialyzed patients. Ren Fail. 2012; 34(6): 727–731.
  44. Reddy MV, Wang H, Liu S, et al. Association between type 1 diabetes and GWAS SNPs in the southeast US Caucasian population. Genes Immun. 2011; 12(3): 208–212.
  45. Wang F, Huang B, Li J, et al. Renalase might be associated with hypertension and insulin resistance in Type 2 diabetes. Ren Fail. 2014; 36(4): 552–556.
  46. Yatsenko SA, Rajkovic A. Genetics of human female infertility†. Biol Reprod. 2019; 101(3): 549–566.
  47. Fatima SS, Rehman R, Martins RS, et al. Single nucleotide polymorphisms in Renalase and KCNQ1 genes and female infertility: A cross-sectional study in Pakistan. Andrologia. 2019; 51(10): e13434.
  48. Catak Z, Kocdemir E, Ugur K, et al. A Novel Biomarker Renalase and Its Relationship with its Substrates in Schizophrenia. J Med Biochem. 2019; 38(3): 299–305.
  49. Skrzypczyk P, Przychodzień J, Mizerska-Wasiak M, et al. Renalase in Children with Glomerular Kidney Diseases. Adv Exp Med Biol. 2017; 1021: 81–92.
  50. Taranta-Janusz K, Roszkowska R, Wasilewska A. Renalase Levels in Children with Solitary Functioning Kidney. Indian Pediatr. 2015; 52(12): 1047–1050.
  51. Lemiesz M, Tenderenda-Banasiuk E, Sosnowska D, et al. Serum Renalase Levels in Adolescents with Primary Hypertension. Pediatr Cardiol. 2018; 39(6): 1258–1264.
  52. Rybi-Szumińska A, Michaluk-Skutnik J, Osipiuk-Remża B, et al. Normal values for urine renalase excretion in children. Pediatr Nephrol. 2014; 29(11): 2191–2195.
  53. Desir GV, Tang L, Wang P, et al. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline. J Am Heart Assoc. 2012; 1(4): e002634.
  54. Fedchenko V, Globa A, Buneeva O, et al. Renalase mRNA levels in the brain, heart, and kidneys of spontaneously hypertensive rats with moderate and high hypertension. Med Sci Monit Basic Res. 2013; 19: 267–270.
  55. Wu Y, Xu J, Velazquez H, et al. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int. 2011; 79(8): 853–860.
  56. Lee HT, Kim JY, Kim M, et al. Renalase protects against ischemic AKI. J Am Soc Nephrol. 2013; 24(3): 445–455.
  57. Zheng WL, Wang J, Mu JJ, et al. Effects of salt intake and potassium supplementation on renalase expression in the kidneys of Dahl salt-sensitive rats. Exp Biol Med (Maywood). 2016; 241(4): 382–386.
  58. Wang Y, Xie BQ, Gao WH, et al. Effects of Renin-Angiotensin System Inhibitors on Renal Expression of Renalase in Sprague-Dawley Rats Fed With High Salt Diet. Kidney Blood Press Res. 2015; 40(6): 605–613.
  59. Gu R, Lu W, Xie J, et al. Renalase deficiency in heart failure model of rats--a potential mechanism underlying circulating norepinephrine accumulation. PLoS One. 2011; 6(1): e14633.
  60. Desir GV, Peixoto AJ. Renalase in hypertension and kidney disease. Nephrol Dial Transplant. 2014; 29(1): 22–28.
  61. Malyszko J, Malyszko JS, Rysz J, et al. Renalase, hypertension, and kidney - the discussion continues. Angiology. 2013; 64(3): 181–187.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl